Up | AC
Home Page
Food and
Drug Administration
Dermatologic and Ophthalmic Drugs Advisory Committee
December 05, 2008
BRIEFING INFORMATION
Morning Session
FDA
Disclaimer
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
FDA Briefing Material (pdf)
Bausch & Lomb, Inc.
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Bausch & Lomb Briefing Material (pdf)
Afternoon Session
FDA
Disclaimer
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
FDA Briefing Material (pdf)
Allergan, Inc.
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Allergan Briefing Material (pdf)